Cheap ASX share better than Woolworths (ASX:WOW)– and it pays dividends

This health device company is rarely mentioned in the same breath as the supermarket giant. But for one expert, it is so much better.

| More on:
a man has an open-mouthed look of surprise on his face as though he's just found out some useful and surprising information.

Image source: Getty Images

You’re reading a free article with opinions that may differ from The Motley Fool’s Premium Investing Services. Become a Motley Fool member today to get instant access to our top analyst recommendations, in-depth research, investing resources, and more. Learn More

Supermarket giant Woolworths Group Ltd (ASX: WOW) has had a loyal following among investors in recent years.

Despite dipping more than 6% this year with the rest of the market, the stock has grown 64% over the past 5 years. This is all while giving out a handy 2.6% in dividend yield.

Groceries are always in demand, regardless of economic cycles. And Woolworths, as market leader, has enviable pricing power to cancel out headwinds like inflation and rising interest rates.

But, believe it or not, there is a growth stock that’s rarely talked about in the same sentence as Woolies, that is comparably better.

That’s the opinion of Firetrail portfolio manager Blake Henricks who has high conviction on Resmed CDI (ASX: RMD) shares.

“It’s a world leader in sleep apnoea,” he told a Pinnacle webinar.

“The reason it’s got such an attractive business is there’s around 400 million people who suffer from a sleep disorder or sleep apnoea. And today, Resmed has 16 million customers.”

Resmed’s biggest rival stumbles

The Firetrail team’s conviction in Resmed ramped up in June last year when its major competitor Koninklijke Philips NV (AMS: PHIA) was forced to recall its sleep breathing machines.

“They’re going to be replacing and repairing 5 million devices,” said Henricks.

“We believe that these market share opportunities that Resmed’s been offered up because of the product recall are material — and will last multiple years.”

The recall is significant because Philips is the second biggest player in the market, immediately behind the leader Resmed.

And the impact of Philips’ misfortune isn’t just a finger-in-the-air guess. Henricks’ team had a precedent in mind.

“We’ve seen this movie before. Cochlear Limited (ASX: COH) had a major recall back in 2011,” he said.

“Subsequently, their market share dropped the next 8 years.”

Resmed vs Woolworths: I know which one I’d choose

The Resmed share price has dropped almost 13% over the past 6 months, but Henricks puts this down to macroeconomic forces.

While the world worries about rising interest rates and wars in Europe, the future potential for the medical device business just cannot be denied, according to Henricks.

“When we compare it to other growth stocks, quality stocks or defensive stocks — of which Resmed is all 3 — we now see an amazing opportunity to buy Resmed at a major discount.”

Henricks added that investors can currently buy Resmed shares for less than 30 times PE [ratio], based on projected financial year 2023 earnings.

“It’s actually not too far away from Woolworths,” he said.

“When we compare the two, Resmed is the clear winner… Resmed is a standout opportunity — it’s got a low valuation and very high growth.”

Resmed shares closed Tuesday at $34.41 each.

Motley Fool contributor Tony Yoo owns ResMed Inc. The Motley Fool Australia's parent company Motley Fool Holdings Inc. has recommended ResMed. The Motley Fool Australia has recommended ResMed Inc. The Motley Fool has a disclosure policy. This article contains general investment advice only (under AFSL 400691). Authorised by Bruce Jackson.

More on Broker Notes

digital screen of bar chart representing asx tech shares
Technology Shares

Broker names 3 of the best ASX tech share to buy in FY23

These tech shares could be buys in FY 2023...

Read more »

a man wearing a hard hat and a high visibility vest stands with his arms crossed in front of heavy equipment at a mine site.
Broker Notes

Should investors dig the Fortescue share price in July?

Fortescue is suffering in the sell-off. Will things get better in July?

Read more »

3 asx shares to buy depicted by man holding up hand with 3 fingers up
Broker Notes

Broker names 3 of the best ASX shares to buy in July

These three ASX shares are highly rated this month...

Read more »

A white and black clock face is shown with three hands saying Time to Buy reflecting Citi's view that it's time to buy ASX 200 banks
Broker Notes

Brokers name 3 ASX shares to buy today

Brokers are bullish on these ASX shares...

Read more »

Three different hands against a blue backdrop signal thumbs up, indicating share price rise on the ASX market
Technology Shares

Why this top broker just slapped a buy rating on Xero shares

Xero shares could be great value according to Morgans...

Read more »

A businessman lights up the fifth star in a lineup, indicating positive share price for a top performer
Broker Notes

Top broker names 3 of the best ASX 200 shares to buy in FY23

These ASX 200 shares have been named as some of the best shares to buy in FY 2023...

Read more »

a woman sits in comtemplation with superimposed images of piles of gold coins, graphs and star-like lights above her head as though she is thinking about investment options.
Broker Notes

2 ASX 200 shares with enough pricing power to battle inflation: Expert

An expert has tipped Transurban and Resmed shares as potential inflation safe havens.

Read more »

A woman sets flowers on a side table in a beautifully furnished bedroom.
Broker Notes

Is the Adairs share price outlook brightening for July?

Should investors make a home for Adairs shares in their portfolio in July?

Read more »